AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06409390
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5.4 mg/kg once every 21 days for 5 cycles
Trial: NCT06409390
Drug: Sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10 mg/kg on days 1 and 8 cycled every 21 days for 5 cycles
Trial: NCT06409390
Drug: Xeloda
RxNorm normalized name: Xeloda
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 orally twice daily for 14 days cycled every 21 days for 5 cycles
Trial: NCT06409390
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg intramuscular (IM) on days 1, 15 and 28 of the first cycle followed by every 28 days for a total of 4 cycles
Trial: NCT06409390
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 600 mg orally daily 21 days on, 7 days off
Trial: NCT06409390
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 150 mg by mouth twice daily
Trial: NCT04541589
Drug: CFZ533 (iscalimab)
RxNorm normalized name: Iscalimab
DrugBank: Iscalimab (DB15260)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological
Trial: NCT05394493
Drug: avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: as provided in real world setting
Trial: NCT06535308
Drug: BnH-015B 40 mg (Dietary impact)
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Korean / 6 on BnH-015B, 2 on placebo
Trial: NCT05394493
Drug: axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: as provided in real world settings
Trial: NCT05263284
Drug: 8-Chloroadenosine
RxNorm normalized name: 8-Chloroadenosine
DrugBank: 8-Chloroadenosine (DB16075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05263284
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05274048
Drug: Neratinib Pill
RxNorm normalized name: neratinib Pill
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will be enrolled in cohorts of 3 at each dose level of Neratinib (120 mg, 160 mg, 200 mg) daily (days 1 through 21)
Trial: NCT05274048
Drug: Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
RxNorm normalized name: fam-trastuzumab deruxtecan-nxki
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: standard dosing of TDxD (5.4mg/m2) on day 1of a 21 day treatment cycle
Trial: NCT05571059
Drug: Ifetroban Sodium
RxNorm normalized name: Ifetroban
DrugBank: Ifetroban (DB12321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral ifetroban
Trial: NCT05681884
Drug: Faricimab
RxNorm normalized name: Faricimab
DrugBank: Faricimab (DB15303)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Faricimab is a humanized bispecific antibody binding to human Ang-2 and VEGF. For Phase III studies, the Ro 686-7461 drug product is provided in single-dose 2-mL glass vials (6 mg/0.05 mL) with L-histidine/acetate buffered solution (approximately pH 5.5) containing sodium chloride, sucrose, L-methionine, polysorbate 20, and water for injection.
Trial: NCT05861999
Drug: risdiplam
RxNorm normalized name: Risdiplam
DrugBank: Risdiplam (DB15305)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive risdiplam orally at the currently approved dose. The dose should be adapted for weight and age.
Trial: NCT06780163
Drug: 17β-estradiol 10 mcg
RxNorm normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17β-estradiol 10 mcg will be given to all participants. The participants will be asked to use 1 tab daily for 2 weeks vaginally before bed, then 1 tab twice a week vaginally before bed until 12 weeks
Trial: NCT05168189
Drug: Ivabradine
RxNorm normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: follow up chronic coronary syndrome patients receiving Ivabradine for ( 6 months ) if the participants develop atrial fibrillation using 24 hours holter .
Trial: NCT04799288
Drug: Teriflunomide
RxNorm normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Teriflunomide 14mg will be administered orally as 1 tablet once daily during the 9-month treatment phase of the study.
Trial: NCT06419777
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin will be used in gestational diabetics to control blood glucose levels
Trial: NCT05758116
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab: 200mg d1,q21d\*17
Trial: NCT05831774
Drug: Intervention - Intraosseous (IO) administration of vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * IV antibiotics (per physician's standard of care): Typically ancef or cefepime is started in pre-op within 1 hour of incision~* IO vancomycin is administered in the OR after sterile prep and draping has occurred (500mg in 100-150mL NS).~* Injection will take place into the proximal humerus
Trial: NCT05242562
Drug: Plenvu
RxNorm normalized name: Plenvu
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a recently developed 1 liter bowel preparation fluid that is often used in clinical practice. Patients will receive a split dose protocol, low-residue diet 2 days before colonoscopy, and clear liquid diet 1 day before colonoscopy.
Trial: NCT05242562
Drug: Moviprep
RxNorm normalized name: MoviPrep
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a 2 liter widely established 2 liter bowel preparation fluid that is commonly used in clinical practice. Patients will receive a split dose protocol, low-residue diet 2 days before colonoscopy, and clear liquid diet 1 day before colonoscopy.
Trial: NCT05310916
Drug: Dapagliflozin 10mg Tab plus another oral hypoglycemic agent
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin is a member of Sodium-glucose co-transporter 2 inhibitors class which in addition to its glucose control effect, has reno-protective and cardioprotective effects, controls blood pressure and causes weight loss.
Trial: NCT05310916
Drug: Two oral hypoglycemic agents other than dapagliflozin
RxNorm normalized name: HYPOGLYCEMIC AGENTS,OTHER
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Two oral anti-diabetic agents not including sodium-glucose co-transporter 2 inhibitors
Trial: NCT05831774
Drug: Control - Standard IV administration of vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive the Houston Methodist Hospital orthopedic surgeon's standard of care pre-operative antibiotic regimen for primary total shoulder arthroplasty patients. This includes IV abx (typically ancef or cefepime and vancomycin) will be started in the pre-operative period approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg \[6,7\] generally 1000-1750mg in 500mL NS).
Trial: NCT04576975
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
Trial: NCT04576975
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
Trial: NCT05660356
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfizer provided GH therapy
Trial: NCT05155917
Drug: Insulin Glargine 300 UNT/ML [Toujeo]
RxNorm normalized name: insulin glargine 300 UNT/ML [Toujeo]
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: insulin glargine sc (0.25 U/kg body weight)
Trial: NCT05297851
Drug: Cytoflavin (succinic acid + inosine + nicotinamide + riboflavin)
RxNorm normalized name: inosinic acid
DrugBank: Inosinic Acid (DB04566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml diluted to 100-200 ml of 5-10% dextroseor 0.9% sodium chloride solution. The rate of administration is 3-4 ml / min. The drug is administered in a volume of 10 ml per injection with an interval of 8-12 hours for 10 days. In severe cases of the disease, a single dose is increased to 20 ml.
Trial: NCT05297851
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard treatment accordind to the routine clinical practice
Trial: NCT00000675
Drug: CD4-IgG
RxNorm normalized name: Human IGG
DrugBank: Recombinant human CD4 immunoglobulin G (DB17812)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05028166
Drug: Mirdametinib (MEK Inhibitor)
RxNorm normalized name: Mirdametinib
DrugBank: Mirdametinib (DB07101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive oral mirdametinib.
Trial: NCT05655819
Drug: Glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 gram powder, one rounded teaspoon, dissolved in 8 ounces of water or juice prior to drinking) taken orally three times per day
Trial: NCT06378021
Drug: Calcium Chloride
RxNorm normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 % calcium chloride injection in cardiac ganglionic Plexus during On pump Coronary artery bypass graft
Trial: NCT06378021
Drug: Sodium Chloride 0.9% Inj
RxNorm normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride injection during on pump during Coronary artery bypass graft
Trial: NCT06349798
Drug: Nefopam
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nefopam in 50 ml of saline, during a 30 min infusion, before end of procedure, then a similer bolus every 4 h for 24 h (6 injections in total) + continuous intravenous infusion of placebo (2 mL/h saline)
Trial: NCT06349798
Drug: Nefopam
RxNorm normalized name: nefopam
DrugBank: Nefopam (DB12293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nefopam in 50 ml of saline, during a 30 min infusion, before end of procedure, then a bolus of placebo every 4 h for 24 h (6 injections in total) + continuous infusion of 100 mg nefopam over 24 h (in 48 mL saline, 2 mL/h)
Trial: NCT06545955
Drug: Nadofaragene Firadenovec
RxNorm normalized name: Nadofaragene firadenovec
DrugBank: Nadofaragene firadenovec (DB17381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vector-based gene therapy for NMIBC treatment to potentiate durable therapeutic responses by interferon (IFN) alfa-2b (IFN-α2b) amplification. It is a non-replicating recombinant adenovirus serotype 5 vector containing a transgene encoding the human IFN-α2b gene.
Trial: NCT06545955
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravesical Gemcitabine chemotherapy, used in combination with Docetaxel.
Trial: NCT06545955
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravesical Docetaxel chemotherapy, used in combination with Gemcitabine.
Trial: NCT06545955
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab is an FDA approved immune checkpoint inhibitor which restores the anti-tumour immune response by blocking the programmed cell death protein 1 (PD-1). Pembrolizumab is administered via intravenous (IV) infusion.
Trial: NCT06439485
Drug: Pemigatinib
RxNorm normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by PO
Trial: NCT06439485
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by PO and IV
Trial: NCT06439485
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by PO and IV
Trial: NCT05263206
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injection solution subcutaneous
Trial: NCT05263206
Drug: Fexofenadine (loratadine if not available)
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet or capsule Oral
Trial: NCT05263206
Drug: Moisturizer
RxNorm normalized name: MOISTURIZER
DrugBank: Oxybenzone (DB01428)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical
Trial: NCT05515562
Drug: Omadacycline Injection
RxNorm normalized name: omadacycline Injection
DrugBank: Omadacycline (DB12455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will receive Intravenous (IV) omadacycline
Trial: NCT03863288
Drug: Oxytocin Intranasal Spray 8 International Unit (8IU)
RxNorm normalized name: oxytocin 5 UNT/ML
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin intranasal spray liquid administration
Trial: NCT03863288
Drug: Oxytocin intranasal spray 24 International Unit (24IU)
RxNorm normalized name: oxytocin 5 UNT/ML
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin intranasal spray liquid administration
Trial: NCT03863288
Drug: Oxytocin intranasal spray 48 International Unit (48IU)
RxNorm normalized name: oxytocin 5 UNT/ML
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin intranasal spray liquid administration
Trial: NCT03863288
Drug: Oxytocin intranasal spray 80 International Unit (80IU)
RxNorm normalized name: oxytocin 5 UNT/ML
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin intranasal spray liquid administration
Trial: NCT06775912
Drug: RD06-05 CART Cell Injection
RxNorm normalized name: prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
Trial: NCT05717361
Drug: ketamine-lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the KL group, patients will be administered in a total volume of 20 mL,1mL/10 kg of the solution containing ketamine, lidocaine at predefined concentrations.~As maintenance, they will be receiving 1mL/10kg/h of the aforementioned solution
Trial: NCT06525428
Drug: standard systemic therapy combined with high/low-dose radiotherapy plus toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-line standard systemic therapies in cohort A include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only), FOLFIRINOX+ bevacizumab.~Second-line standard systemic therapies in cohort B include: FOLFOX/XELOX+ bevacizumab, FOLFOX/XELOX+cetuximab (KRAS/NRAS/BRAF WT), FOLFIRI/irinotecan+raltitrexed/irinotecan/+bevacizumab, FOLFIRI/irinotecan+raltitrexed/irinotecan/+cetuximab (KRAS/NRAS/BRAF WT), based on the previous first-line chemotherapy and adverse events.~Toripalimab will be given at 240 mg q3w. Radiotherapy regimes include 4-8 fractions of 4-12Gy via SABR or hypofractionated radiotherapy (HFRT) and 5 fractions of 0.5-2Gy via LDRT
Trial: NCT05758246
Drug: Fisetin-dose 1
RxNorm normalized name: FISETIN
DrugBank: Fisetin (DB07795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg/kg once a day for one day.
Trial: NCT05758246
Drug: Fisetin-dose 2
RxNorm normalized name: FISETIN
DrugBank: Fisetin (DB07795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg/kg once a day for two days
Trial: NCT05808608
Drug: AK104
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-PD-1/CTLA-4 bi-specific antibody drug; RP2D intravenously (IV)
Trial: NCT05808608
Drug: Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An oral, small molecule, TKI selective for VEGFRs; 5mg bid orally
Trial: NCT05134688
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tocolytic to stop preterm labor
Trial: NCT05164536
Drug: Amyvid
RxNorm normalized name: Amyvid
DrugBank: Florbetapir F-18 (DB09149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will undergo a single β-amyloid PET scan with Amyvid.
Trial: NCT05291091
Drug: Sevasemten 10 mg
RxNorm normalized name: Sevasemten
DrugBank: Sevasemten (DB18983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevasemten is administered orally once per day
Trial: NCT05291091
Drug: Sevasemten 5 mg
RxNorm normalized name: Sevasemten
DrugBank: Sevasemten (DB18983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevasemten is administered orally once per day
Trial: NCT05291091
Drug: Sevasemten 12.5 mg
DrugBank: Sevasemten (DB18983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevasemten is administered orally once per day
Trial: NCT05693935
Drug: TV-44749 - Dose level 1
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Period 1, 2 monthly injections. In Period 2, up to 12 monthly injections
Trial: NCT05693935
Drug: TV-44749 - Dose level 2
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Period 1, 2 monthly injections, In Period 2 up to 12 monthly injections
Trial: NCT05693935
Drug: TV-44749 - Dose level 3
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Period 1, 2 monthly injections. In Period 2, up to 12 monthly injections
Trial: NCT05722522
Drug: Secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The participants will receive Secukinumab 300 mg s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
Trial: NCT05352763
Drug: simufilam
RxNorm normalized name: Simufilam
DrugBank: Simufilam (DB18817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simufilam 100 mg oral tablets
Trial: NCT06462079
Drug: Sacituzumab Govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients were treated with Sacituzumab Govitecan 10 mg/kg in 21-day treatment cycles with intravenous infusions on days 1 and 8 and continued until disease progression or unacceptable toxicity.
Trial: NCT05285397
Drug: Liraglutide Pen Injector [Saxenda]
RxNorm normalized name: liraglutide Pen Injector [Saxenda]
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection of GLP-1 agonist
Trial: NCT06247462
Drug: Placebo Corn Starch
RxNorm normalized name: Corn Starch
DrugBank: Corn (DB10572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of corn starch (placebo) was ingested 12- and 1-hours prior to exercise.
Trial: NCT05165485
Drug: Revefenacin
RxNorm normalized name: Revefenacin
DrugBank: Revefenacin (DB11855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Revefenacin 175 mcg administered once daily for 84 days via nebulization
Trial: NCT05165485
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 mcg administered once daily for 84 days via Spiriva HandiHaler®
Trial: NCT05165485
Drug: Revefenacin Placebo
DrugBank: Revefenacin (DB11855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo for Revefenacin administered once daily for 84 days via nebulization
Trial: NCT05165485
Drug: Tiotropium Placebo
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Tiotropium administered once daily for 84 days via Spiriva HandiHaler®
Trial: NCT06069726
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of atezolizumab will be given prior to resection.
Trial: NCT05366335
Drug: Live Combined Bifidobacterium and Lactobacillus
RxNorm normalized name: Bifidobacterium animalis / Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The invesitigators give patients Live Combined Bifidobacterium and Lactobacillus solution infusion during their colonoscopy examination for a single time in the Live Combined Bifidobacterium and Lactobacillus group.
Trial: NCT04940091
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia is performed with a mixture of local anesthetics (ropivacaine) and opioids (sufentanil).
Trial: NCT05681702
Drug: aspirin plus clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After at least 30 days of DAPT \[with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will continue aspirin and switch to clopidogrel 75-mg.